'Update related to the Scheme of Amalgamation of Dhanuka Laboratories Limited ("Amalgamating Company") with…
As filed · Orchid Pharma Limited has informed the Exchange regarding 'Update related to the Scheme of Amalgamation of Dhanuka Laboratories Limited ("Amalgamating Company") with Orchid Pharma Limited ("Amalgamate
What happened
FactOrchid Pharma Limited has informed the Exchange regarding 'Update related to the Scheme of Amalgamation of Dhanuka Laboratories Limited ("Amalgamating Company") with Orchid Pharma Limited ("Amalgamated Company/Company") and their respective shareholdersand creditors ("the Scheme") under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended.'. Orchid Pharma Limited Regd. Exchange Plaza, Bandra Kurla…
Why it matters
CapitSignal interpretationA merger fixes a share-exchange ratio, which permanently sets how much of the combined company existing holders own.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
DelayedWe'll probably have the exact number, say, after a few months' time.
as our cefiderocol project will get started, say, in the next year, then we will take validation batches and hopefully, after two years, we would be able to -- once we are able to register the product from our side, we would be able to supply some percentage from our side.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Swap ratio and its valuation basis
- Regulatory and NCLT approvals required
- Appointed date
- Hopefully, within this quarter, we should announce one. (management committed by Q4 FY26)
- The first sales actually would be to Orchid itself internally. (management committed by Q1 FY27)
Evidence
How CapitSignal classified this
- Reasoning:
- MERGER base 74; +2 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%